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Abstract
Background: The work of Research Ethics Boards (REBs), especially when involving genetics
research and biobanks, has become more challenging with the growth of biotechnology and
biomedical research. Some REBs have even rejected research projects where the use of a biobank
with coded samples was an integral part of the study, the greatest fear being the lack of participant
protection and uncontrolled use of biological samples or related genetic data. The risks of
discrimination and stigmatization are a recurrent issue. In light of the increasing interest in
biomedical research and the resulting benefits to the health of participants, it is imperative that
practical solutions be found to the problems associated with the management of biobanks: namely,
protecting the integrity of the research participants, as well as guaranteeing the security and
confidentiality of the participant's information.
Methods: We aimed to devise a practical and efficient model for the management of biobanks in
biomedical research where a medical archivist plays the pivotal role as a data-protection officer.
The model had to reduce the burden placed on REBs responsible for the evaluation of genetics
projects and, at the same time, maximize the protection of research participants.
Results: The proposed model includes the following: 1) a means of protecting the information in
biobanks, 2) offers ways to provide follow-up information requested about the participants, 3)
protects the participant's confidentiality and 4) adequately deals with the ethical issues at stake in
biobanking.
Conclusion: Until a governmental governance body is established in Quebec to guarantee the
protection of research participants and establish harmonized guidelines for the management of
biobanks in medical research, it is definitely up to REBs to find solutions that the present lack of
guidelines poses. The model presented in this article offers a practical solution on a day-to-day basis
for REBs, as well as researchers by promoting an archivist to a pivotal role in the process. It assures
protection of all participants who altruistically donate their samples to generate and improve
knowledge for better diagnosis and medical treatment.
Background
In Canada, Research Ethics Boards (REBs), also known as
Research Ethics Committees (RECs), Institutional Review
Boards (IRBs), and Ethical Review Boards (ERBs), have
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the mandate to approve, reject, propose modifications to,
or terminate any proposed or ongoing research involving
human subjects which is conducted within, or by mem-
bers of, the institution, using the considerations set forth
according to the Tri-Council Policy as the minimum
standard. The authority of the REB being delegated
through the institution's normal process of governance
[1]. In Quebec, most REBs are under the administrative
supervision of the Administrative Council of each medical
centre. In fact, the everyday realities of life as a patient and
health care provider or research subject and researcher are
framed by the institutional settings of health care and
research institutions [2].
REBs have, as primary concerns, the protection of the
integrity of participants, the need for participants to
receive simple but efficient information in order to grant
an informed consent, the maintenance of confidentiality
of participant's data, and decisions to inform the partici-
pants on the research being conducted and the transmis-
sion of research results (if applicable). It was accurately
stated that "Institutional Review Boards have considerable
experience in dealing with issues of recruitment, informed
consent, confidentiality, and balancing risks and benefits.
The context of commercial biobanking, however is rela-
tively new" [3]. With the advancement of biotechnology
and the growth in biomedical research, the role of REBs
has become more complex, especially regarding research
in genetics and related biobanks. The competence of REBs
has been extended "to protocols potentially affecting not
only the physical integrity, but also the identity (social
and familial) of an individual, bringing psychological and
spiritual aspects to the forefront" [4].
Considering that there are no specific regulations in Que-
bec, nor in the rest of Canada to control the creation and
management of biobanks arising from institutional
research projects, major ethical issues are on the rise and
are often left to be managed by REBs and their affiliated
institution. Nevertheless, the Research Ethics Committees
appear to be appropriate bodies for evaluating research
projects involving biobanks [4]. Recently, in Quebec, a
newly-formed Institute for Populations, Ethics and Gov-
ernance [5] has been created. It is a non-profit organiza-
tion with the initial mission of coordinating large-scale
research projects related to population genetics, genomics
or proteomics taking place in member institutions. It had
the initial mandate of managing the CARTaGENE project
[6] and other biobanks in Quebec that wish to be so gov-
erned [7]. Therefore, every academic or research institu-
tion in Quebec with the above interests can become a
member [5,7], but is not obligated to. Presently, there is
no governmental governance body, in Quebec, nor in the
rest of Canada, to manage biobanks stemming from aca-
demic or institutional research projects. In fact, there are
no established harmonized guidelines that could give
directions to REBs in managing biobanks in order to
insure the protection of research participants.
Consequently, the following difficult questions about
biobanks are emerging on a daily basis for REBs: 1) How
can a REB deal with the growing demands for collecting,
processing and storing biological samples and related
information in genetic research projects? 2) When a par-
ticipant in a research project gives his consent for the stor-
age of samples in biobanks, how can the REB provide
adequate privacy protection for him? 3) How is it possible
to maintain the security and integrity of the research par-
ticipants with the use of coded samples? (In fact, the
demands for coded samples are becoming the rule com-
pared to the use of anonymous samples just a few years
ago). 4) How is it possible for REBs to protect the confi-
dentiality and security of genetic information arising from
these biobanks? 5) How can the storage of biological
materials be managed for an indefinite period of time as
often requested by sponsors, funding bodies and pharma-
ceutical companies? 6) What are the assurances given by
REBs to research participants that their "informed con-
sent" for the storage of their samples in biobanks is fully
respected? 7) In the event of a discovery with clinical util-
ity, how is it possible to recontact the research participants
while respecting the confidentiality issue?
In light of the increasing interest in biomedical research
[3,4,8,9] and the resulting benefits to the health of partic-
ipants, it is imperative that practical solutions be found to
the problems associated with the management of
biobanks: namely, the protection of the integrity of the
research participants, as well as guaranteeing the security
and confidentiality of their information data. REBs also
have a dual responsibility: firstly, to safeguard the dignity,
rights, safety and well-being of research participants; sec-
ondly, to facilitate the good conduct of high quality
research [10,11], without jeopardizing the integrity of
research participants.
As members of institutional REBs for many years, we have
noticed these growing concerns among our colleagues in
trying to find answers to the questions raised above and
the overall management of biobanks in genetics research.
A recent Canadian survey among 43 REBs has clearly dem-
onstrated the variability of answers and the difficulties
arising from a fictional protocol involving the creation,
use and management of biobanks in a genetic study. REBs
were asked: Do you think that this protocol is ethically
acceptable by your REB? 23% refused the protocol cate-
gorically, 26% wanted the protocol to be reviewed by the
PI before deciding, 26% refused on condition of certain
modifications, 14% stipulated that the protocol was not
within their mandate, 9% accepted the protocol but underBMC Medical Ethics 2006, 7:4 http://www.biomedcentral.com/1472-6939/7/4
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certain conditions and only 1% approved it without con-
ditions [12]. In another study, 44 Canadian biomedical
REBs agreed to review a mock research protocol in func-
tional neuroimaging involving biobanks. The distribution
of decisions made by the participating REBs is as follows:
68.2% rejected the protocol because of the creation of a
biobank, 22.7% approved the protocol but under certain
conditions, 6.8% approved unconditionally and 2.3%
preferred not to answer. Interestingly, among the 68.2%
of REBs who rejected the protocol, 37% expressed con-
cerns about access to research subjects' medical records,
30% questioned the building of a database and 30% men-
tioned that the study involving biobanks did not fall
under their mandate or area of expertise [13]. These two
studies reaffirm the great variability of motives and crite-
ria involved in the decision-making process for REBs.
Their difficulties in managing research projects with
biobanks often pose barriers to research.
REBs evaluating genetic research projects also have to deal
with a dual problematic: first, the samples collected in the
principal study are almost always coded by the principal
investigator who remains the keyholder; second, there are
growing demands from pharmaceutical companies and
funding agencies to store residual samples. Also, there are
requests for additional samples from the same partici-
pants and the storage of these additional samples in
biobanks for an indefinite number of years. There is thus
an increasing need to deploy adequate measures of confi-
dentiality and protection of the integrity of the research
participants without jeopardizing information that could
benefit the entire research process and, in the end, be of
major importance to the health of the participants.
In this article, we present a practical model for the man-
agement of biobanks in biomedical research, which could
alleviate the burden placed on REBs who are trying to
evaluate genetics projects and at the same time, maximize
the protection of research participants. Consequently, we
will address the protection of the information related to
biobanks, the means to provide follow-up information
about the participant without breaching confidentiality,
the possibility of recontacting the participants in the event
of a clinical utility stemming from the research with
biobank samples and the ethical issues at stake for partic-
ipants in biobanking. But first, let us define the terminol-
ogy of "biobanks" and the "identifiability of samples" or
biological materials stored in biobanks.
Methods
Biobanks
Biobanks refer to organized collections of biological sam-
ples and the data associated with them [14]. In the context
of genetic research, biobanks are defined as a cluster of
biological samples obtained from a group of identified
individuals selected according to the clinical or biological
characteristics of one or more members of the group, as
well as any and all derivatives of these samples [4]. The
American National Bioethics Advisory Commission
defined a DNA bank as a "facility that stores extracted
DNA, transformed cell lines, frozen blood or other tissue,
or biological materials, for future DNA analysis". The
same Commission defined a DNA databank as "a reposi-
tory of genetic information obtained from the analysis of
DNA, sometimes referred to as "DNA profiles". DNA sam-
ple collections are used for various purposes, such as for
clinical, research and industrial uses [15]. Human biolog-
ical samples in biobanks include organs (heart, liver, kid-
ney, lung, pancreas, etc.), tissues, cells (somatic and
gonadic), body fluids, hair, nails and body waste products
[16]. Thus, biobanks are an important resource for identi-
fying the causes and mechanisms of a large number of dis-
eases, including, in particular, those that are widespread
among the population [11]. Our ever greater understand-
ing of the human genome is increasingly making it possi-
ble to determine the role, not only of environmental or
lifestyle factors, but also of hereditary factors (genes) as
the cause or disposition to disease (genetic epidemiology)
[11].
Biobanks may be operated under the auspices of public
sector institutions, such as university departments, indi-
viduals or private bodies – for example, pharmaceutical
companies. Irrespective of the responsible institution,
they may get funding from public or private sources [11].
In this article, we will address the problems facing
biobanks created for institutional or academic research
projects only, either publicly or privately funded.
Identifiability of samples for research purposes
Ambiguity is often the case when referring to identifiabil-
ity of samples for research purposes. A few years ago, the
American Society of Human Genetics described four types
of identification of samples for research purposes: a)
anonymous: biological materials that were originally col-
lected without identifiers and are impossible to link to
their sources; b) anonymised: biological materials that
were originally identified, but have been irreversibly
stripped of all identifiers and are impossible to link to
their sources; c) identifiable or coded or traceable: biolog-
ical materials that are unidentified for research purposes,
but can be linked to their sources through the use of a
code. Decoding can only be done by the investigator or
another member of the research team; d) identified: bio-
logical materials to which identifiers, such as name,
patient number, or clear pedigree location, are attached
and made available to the researchers [17]. Recently, the
European Agency for the Evaluation of Medicinal Prod-
ucts gave some guidance in dealing with coded samples,
adding the category "double-coded samples and results",BMC Medical Ethics 2006, 7:4 http://www.biomedcentral.com/1472-6939/7/4
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where a first code is assigned to the sample and a second
code is provided to link it to the results. The keycode link-
ing the double coded pharmacogenomic samples and the
information is kept by a third party. The research subject
can only be linked with the sample or data obtained from
it by bringing the two code keys together [18].
Even taking into account these precise definitions there is
a tremendous variability in interpretations among REBs,
regarding the four classes of identifiability [19]. So, in this
article, we will be focusing mainly on issues concerning
identifiable or coded samples in biobanking, also referred
to as pseudonymized samples [11].
Procedure for the collection of specimens in institutional 
research projects
Let us consider the procedure for the collection of biolog-
ical samples in institutional research projects often
requested in the scope of a multi-centric trial by funding
bodies, such as pharmaceutical companies. After the
approval of the research project by the REB and after a
signed informed consent from the participants is
obtained, the collection of biological samples is per-
formed by the principal investigator's nurse coordinator
at the clinical research centre affiliated to a medical centre
where the patients are usually clinically treated and fol-
low-up occurs. The samples are usually identified or
coded with an alphanumeric code under the responsibil-
ity of the principal investigator (PI). Only the PI and a des-
ignated research coordinator have the keycode related to
identifiers such as the name, date of birth, age, sex, dis-
ease, treatment, etc. The coded samples are then sent to
the pharmaceutical or sponsoring company funding the
project where haematological, biochemical, radiobiologi-
cal, DNA analyses, etc. are done. Some research will look
at the genotypic variation, others at the gene expression
(at the RNA or protein level), and others still at the viral
or tumoral genotype [20]. Often, in these multi-centric or
international projects, samples from many collaborating
countries are sent to a central lab where the analyses are
performed by trained personnel using validated and uni-
form techniques.
In principle, it is not possible for the funding bodies to
access the codes and thus find a link to the source. How-
ever, the American Society of Human Genetics (ASHG)
recommended that investigators inform individuals that
they cannot guarantee absolute confidentiality [21]. The
ethics committee of the ASHG recommended that
researchers "consider a way of coding samples by a third,
independent party, who would keep the codes inaccessi-
ble unless there are specific circumstances in which the
code needs to be broken" [15].
Also, what is often the case in pharmacogenetics research,
a second specimen or residual specimen is requested for
molecular genetics studies in order to better understand
the disease, its response to drug and the possible adverse
events. These samples are requested for storage in
biobanks at the company's facilities, usually for an indef-
inite period of time. Currently, there is a growing need for
coded second-specimen samples (in the past, such request
samples were anonymous) and these requests involve
serious ethical issues that must be dealt with by REBs.
Ethical issues at stake for research participants in 
biobanking
There is a pluralism of values at stake as regards to
patients, research participants, authorities, the medical
profession, scientists and the general public concerning
the storage and use of human tissue samples [22,23], the
importance of which may vary according to the individual
involved.
1. Informed consent
It is generally accepted that the necessity of "Informed
Consent" within the context of research is an absolute
imperative [24]. In research involving biobanks, there are
two main principles to be respected for the benefit of the
participant who agrees to provide samples: obtaining his
informed consent and determining the risk/benefit bal-
ance by the REB. Putting forward a legal framework for
research involving biobanks, the German National Ethics
Council, in a recent opinion, states as its first guiding prin-
ciple, that "the central element of all regulatory proposals
must be the donor's right of self-determination. This
means that the collection of substances from his body and
the gathering of personal data, for subsequent use in
biobanks for the purposes of medical research, must be
subject to the donor's consent. The consent is effective if
the donor has the capacity to give consent, the consent is
given voluntarily and the donor has been appropriately
informed of the purposes, nature, significance and impli-
cations of the collection and use" [11]. After assessing the
voluntary nature of the participation, it is the responsibil-
ity of the REBs to evaluate other important issues such as
the possibility of stigmatization or discrimination in dis-
crete subpopulations, traditional communities, such as
indigenous peoples [11] (even if the research subjects
samples are coded) and the possibility of benefit sharing
of revenues that could be generated by the research.
It was recently mentioned that, "while it is possible to
obtain informed consent to have one's blood, cells or tis-
sue samples taken by researchers for a specific research
project, the very intention of setting up such large data
banks precludes giving informed consent for all the possi-
ble ways in which the information derived from that sam-
ple can be used for future research" [3]. But, given theBMC Medical Ethics 2006, 7:4 http://www.biomedcentral.com/1472-6939/7/4
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speed of scientific development in the area of genetics and
the vast spectrum of potential research hypotheses that
may arise and can legitimately be addressed by such data-
banks, there is no way to predict possible future uses of
donated samples [25]. It is up to the REB to "develop their
own guidelines to evaluate research with stored biological
materials" [20,26] to respect the consent of participants.
An interesting recent survey revealed that the donor
informed consent procedures in tissue-based research
should be rethought: perhaps information about research
objectives is seen more as a service than a safeguard (i.e.,
is nice to have but not important), which would imply
that bioethicists should work to ensure safeguards other
than informed consent. In fact, it has been suggested to
focus attention on the establishment of tissue-trustee
infrastructures, rather than consent issues, to ensure the
confidence of the donating public [27].
Nevertheless, it is essential for REBs to put in place means
for the logistics involved in the uses of donor's specimens
stored in biobanks for the purposes of medical research.
2. Confidentiality issue
Areas of concern related to confidentiality in the context
of commercial biobanking include handling of identifi-
ers, physical and other kinds of security, and transfer of
samples and information [28,29]. The breach of confiden-
tiality resulting from the mishandling of personal infor-
mation is an important issue in pharmagenomics (and
pharmacogenetics). This informational risk is due to the
personal, familial, and social nature of genetic informa-
tion as well as its potential to discriminate and stigmatize
[20]. Points to consider by researchers and Institutional
Review Boards (IRBs) have recently been suggested in
determining various levels of confidentiality, within the
framework of pharmacogenomics research where
researchers decide the level of protection best suited for
their research protocols [20]. Clearly, both researchers
and IRBs will need to work in unison, on a case by case
basis, with participant confidentiality as a primary con-
cern. In the end, IRBs will have to evaluate the final
acceptable level of confidentiality.
One of the guiding principles of the German National
Ethical Council is that donors must be protected by an
Schematic diagram of management model for biobanks Figure 1
Schematic diagram of management model for biobanks. (Shaded areas are for biobank management)
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obligation of confidentiality on the part of all involved in
the establishment and use of biobanks. When not pro-
vided by law, this obligation of confidentiality must be
imposed by the institution itself, either in its statutes or by
contract [11]. A study to determine if REBs provided ethi-
cal guidance in research involving stored biological speci-
mens revealed that, although most REBs mention the
confidentiality issue, "fewer than 30% suggested steps for
protecting confidentiality" [26]. Hence, it is up to each
REB to be vigilant in respecting the statutes of its own
institution and also in establishing protocols and guide-
lines (if not already established) to ensure protection of
the genetic data information of the research participants.
3. Privacy issue and protection of information
A recent survey in Sweden revealed that in spite of wide-
spread bioethical debate about the presumed sensitivity of
genotype information, management of medical records
and clinical data appear to remain of great concern to the
donating public [30]. Guidelines developed by the Ethics
Committee of the Swedish Medical Research Council
stress the importance of protecting individual data and
advise that codes linking data held in a biobank to an
individual should be kept within a public institution such
as a university or medical authority [31]. If inadequate
attention is paid to security, unauthorized individuals can
access electronically stored information and use it for
illicit purposes. As a result people are increasingly worried
about their privacy and want stricter control over who has
access to information about them and under what condi-
tions [19,32]. Issues of privacy have become entangled
with bioinformatics as, increasingly, we rely on technol-
ogy rather than on human beings to resolve privacy issues
[33]. Fears of discrimination by employers and insurers
are definitely of increasing importance for participants in
genetic research. Many may fear that their genetic infor-
mation could be shared with third parties (insurers,
employers), who sometimes require that the individual
provide a general release of his medical records or infor-
mation relating to his participation in research projects.
It is essential that operational rules be established by REBs
so that the conditions of access to biobanks are clearly
determined and are acceptable to the research partici-
pants.
Results
A proposed biobank management model for institutional 
research
We propose a model for the management of biobanks in
biomedical research. Figure 1 represents a schematic
description of this model, taking into account the admin-
istration levels encountered in a medical centre. This
model is based on the use of two codes, each being specif-
ically attributed to a definite part of the study: Part 1: col-
lection of samples with a specific code (code 1) for the
research project and Part 2: collection of samples with a
specific code (code 2) to be stored in a biobank for genetic
analyses.
Part 1 (Code 1)
After approval of the research project by the REB and
informed consent obtained from willing participants,
samples are collected and coded. For this main study, an
alphanumeric code (code 1) is given to each sample. The
principal investigator of the project, at the institution, is
responsible for keycode no. 1. The coded samples are then
usually sent to the pharmaceutical company for analyses,
as previously described.
Presently, the PI is the one responsible for managing the
schedule of conservation, as well as the destruction and
withdrawal of the coded samples. In the model presented
herein, the PI has the option of bestowing this responsi-
bility on a medical archivist, who has to respect the law
and regulations applicable to managing archives in medi-
cal centres, the archivist being a key person in maintaining
the confidentiality [34,35]. Since clinical researchers, in
an academic institution, are also practicing physicians,
teaching, as well as doing research in many projects
(multi-centric or not), they can go on sabbatical, be on
vacation, take sick-leave and eventually retire, it could
probably be a very interesting option for them to have a
professional medical archivist at their medical centre tak-
ing care of this very important task of managing coded
samples from research projects. Since coded research sam-
ples may be kept for a period of time that may vary from
a few weeks to many years, depending on the protocol of
the funding bodies, a schedule of conservation and man-
agement of samples could be established in collaboration
with the researcher, upon acceptance of this procedure.
Therefore, the archivist would receive the keycode for that
particular research project, and effectively manage the
samples on a daily basis, always in close cooperation with
the PI. We thus propose a collaboration between PI and
archivist to maintain an efficient way of managing coded
samples necessary for the main study.
Part 2 (Code 2)
The second part of the study represents the collection of
samples for the biobank. The responsibilities and obliga-
tions of the PI can be divided into 3 important sections in
this biobank part of the project: 1) to evaluate whether the
ethics principles involved are respected in the creation of
the biobank, as well as the need, reasons, objectives and
scientific importance for biobanking in the first place; 2)
to explain the preceding section to the REB and to provide
answers to their questions; 3) upon acceptance of the cre-
ation of the biobank by the REB, the PI must explain to
the research participants, in the most comprehensibleBMC Medical Ethics 2006, 7:4 http://www.biomedcentral.com/1472-6939/7/4
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way, the scientific importance of giving their biological
samples to the biobank and all circumstances likely to be
relevant to their decision to grant or refuse the biobank-
ing, such as the need, the purposes, the nature, the scope
and duration of the proposed use, the extent and condi-
tions of a possible transfer of samples and data, the form
of data storage and linkage, the possibility of withdrawal
of consent at any time, the commercial prospects, the ben-
efit sharing [11], the possibility of being recontacted (or
not) in the event of a discovery of medical utility and
inform them about the role of the archivist, as the person
in charge of the management of the biobank. These are
crucial responsibilities and obligations that the PI can not
delegate to the archivist.
As mentioned previously, REBs must approve biobanking
and set detailed conditions for access to the biobanks and
their use. The research participants, after receiving com-
plete information about the biobank and responses to
their possible questions, sign a separate consent form in
which they agree to donate their biological samples to the
biobank. In the proposed model, an alphanumeric code is
then attributed, by a medical archivist, to each sample
(code 2). The samples are then sent to the central labora-
tory of the company, where the analyses are performed.
The only person having the keycode no. 2 is the archivist.
The archivist, as a third party, has the role of a data-protec-
tion officer [11,36,37] or trustee [28] who is independent
from the research project. However, this role is relatively
different from an honest broker system [38]: first, the
archivist is appointed by the institution, under the respon-
sibility of the Director of Professional Services of the med-
ical centre and in accordance with the Clinical Research
Centre, where the research is performed, not the REB (as
often seen with the honest broker system). Secondly, the
educational training, role, duty, obligations and responsi-
bilities of the medical archivists are different, in compari-
son to an honest broker, who can be a nurse, a clinical
clerk and/or a computer software system, etc. Also, the
archivist has been trained to adequately manage the
schedule of retention of charts in a medical centre, so it
would be easy to apply the same principles to coded sam-
ples in a research project (conservation, destruction, with-
drawal). The archivist will ensure the protection of data
and supervise the biobank. Hence, it is the responsibility
of the archivist to ensure good compliance with the legal
requirements applicable when handling personal infor-
mation and data [34,35]. Regarding ethics principles
involved, the archivist has the obligation to respect the
Code of Ethics and politics of confidentiality instigated by
the medical centre, and legally, the different laws applica-
ble in Quebec, such as the Archives Act and Regulations
[34,35], the Health services and social services Act [39],
the Civil Code of Quebec [40], the Access to documents
held by public bodies and the protection of personal
information Act [41]. The role of the archivist is thus
under the governance of ethical and legal frameworks,
that are oriented towards the protection of the integrity of
patients, who can also be research participants in biomed-
ical research.
Furthermore, it was recently recommended that the
researcher can not have access to keycode no. 2 "so that he
cannot by himself link them to the person concerned. In
this case, as in that of anonymization, the researchers lack
the possibility of relating samples and data to their
donors" [11,36]. The reality of biobanks is such that the
role of the PI is very limited. He is not responsible for the
genetics research being done at the pharmaceutical com-
pany, nor is he implicated in the direction that the
research will take. He may however be asked to give infor-
mation regarding the medical condition of the research
participant, the side effects of a specific drug, etc. The role
of the archivist as a data-protector is essential in coordi-
nating and answering these particular questions.
Furthermore, in the event of a clinical utility stemming
from the research with biobank samples, it could be
important to recontact the research participants. The phar-
maceutical companies and funding agencies would then
have to contact the PI to reveal the importance of the dis-
covery and the need to recontact the participants. After
confirming the importance of the discovery and the need
of recontacting the participants, the PI would then resub-
mit this new demand to the REB of his institution. The
REB would have the responsibility to evaluate the merits
of recontact, the proportionality of risks and benefits
involved and even in certain cases, the probable social
consequences that could arise. If there is an approval by
the REB to recontact the participants, the REB would then
inform the archivist who would verify if the participants
have previously agreed in their consent form to be recon-
tacted. If so, the archivist could proceed to recontact the
participants and inform them of the particular beneficial
situation. A meeting with the PI would then be scheduled
for further explanation.
The archivist plays an essential role in this model, since
he/she holds the research protocol and the signed consent
form from the participant, in order to verify that his
wishes are in accord with the agreement established at the
start of the project. Apart from being the keyholder of cod-
ing no. 2, the archivist will also be responsible for the
schedule of conservation, the destruction or for the with-
drawal of specimens. Also, a participant who decides to
terminate his participation in the project will have the
opportunity to withdraw at any time from the study, the
samples being coded. In addition, if the pharmaceutical
company decides to ask questions relating to the clinical
aspects of the project, such as the response of the partici-BMC Medical Ethics 2006, 7:4 http://www.biomedcentral.com/1472-6939/7/4
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pant to a specific drug, his current medical situation, etc.,
the archivist will be able to answer the questions, while
ensuring the confidentiality of data.
Discussion
The model for managing biobanks presented herein is
simple, efficient, and offers interesting practical possibili-
ties for Research Ethics Boards, the researcher and the
funding bodies, and mostly, is of major importance for
the protection of the integrity of the research participant.
The proposed model is novel regarding the fact that it
does not require new personnel, committees or training of
any kind. In fact, it favours the use of trained medical
archivists, who are part of an infrastructure already in
place in a medical centre, and who have proven to be effi-
cient throughout the years in managing charts of patients,
under specific laws and a strict code of ethics, to assure the
management of the research biobanks. It also answers
questions mentioned in the introduction, regarding the
day-to-day collection, storage and processing of samples
in biobanks. It insures a high degree of confidentiality,
security of data information and protection of the integ-
rity of the participants while using coded samples in the
biobank that are distinct from that in the main research
project. It offers the possibility of managing stored biolog-
ical samples for a prolonged period of time, allowing
research participants to withdraw their samples at any
time, by a simple request to the archivist. It also favours
the possibility for the funding body of asking information
about the medical condition of the participant taking part
in the research project, without breaching confidentiality.
If a discovery of a medical utility arises, it is also feasible
under this model to recontact the research participants.
These aspects are of major importance to the REB enabling
it to ensure better protection of the integrity of the
research participant. Evidently, the use of two non-related
keycodes (keycodes 1 and 2), where the researcher has no
access to keycode 2 for the samples and related informa-
tion for the biobanks (he cannot by himself tie them to
the participant), favours the highest level of confidential-
ity and security of the biobank data for the participant.
The model also respects the informed consent of the
research participant, while having a health-care profes-
sional, such as an archivist or data-protection officer, in
charge of the biobank and to whom they have entrusted
their biological samples, as well as the related information
and data. This situation will promote an evolutive,
dynamic communication process between the funding
body and the data-protection officer, facilitating
exchanges of information. In the overall procedure, this
model will also permit the sharing of valuable medical
information on the participant, since the keycode offers a
link to the biobank analyses, this may enhance the reper-
cussions of the research project. The participant can also
decide to withdraw his consent for the use of his samples
and related data at any time, simply by asking the archi-
vist. It also offers the possibility for the funding body to
provide results of the research done to the participants, if
they agreed to this in the first place in their informed con-
sent.
Conclusion
As long time members of REBs, we have been able to
assess the burden on REBs in trying to evaluate research
projects involving the use of storage samples in biobanks.
The recurrent problems concerned the assurance of pro-
tection of the integrity of the participant, as well as the
confidentiality and security of related data. We have pre-
sented two surveys clearly demonstrating the difficulties
for REBs to manage research projects with biobanks and
the high percentage of rejection of protocols involving the
use of biobanks where coded samples were an integral
part of the study. The greatest fear encountered being the
lack of participant protection and uncontrolled use of bio-
logical samples or related genetic data. The risks of dis-
crimination and stigmatization being a recurrent issue.
Until a governmental governance body is established in
Quebec to guarantee the protection of research partici-
pants and establish harmonized guidelines for the man-
agement of biobanks in medical research, it is definitely
up to REBs to find solutions. We therefore think that this
model of biobanks management in medical research will
offer an interesting solution on a day-to-day basis for
REBs (hopefully in many countries), as well as for
researchers, and in the end, assure protection of all partic-
ipants who altruistically donate their samples to generate
and improve knowledge for better diagnosis and medical
treatment.
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